Inicio Zine News Applied Therapeutics Announces Initiation of Phase 3 Registrational Trial of AT-001 in...

Applied Therapeutics Announces Initiation of Phase 3 Registrational Trial of AT-001 in Diabetic Cardiomyopathy (ARISE-HF)

1
0

NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the initiation of a Phase 3 registrational trial for AT-001, a novel, potent and selective aldose reductase inhibitor (ARI), in Diabetic Cardiomyopathy (DbCM). The study, called ARISE-HF, will investigate AT-001’s ability to improve or prevent the decline of functional capacity in patients with DbCM at high risk of progression to overt heart failure.